CBS-0550
From Wikipedia, the free encyclopedia
Identifiers | |
---|---|
|
|
CAS Number | 887289-02-3 |
PubChem (CID) | 24763642 |
ChemSpider | 23320245 |
Chemical and physical data | |
Formula | C20H23F4N3O |
Molar mass | 397.409 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]
See also[edit]
References[edit]
- ^ Ohta H, et al. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorganic and Medicinal Chemistry. 2008 Feb 1;16(3):1111-24. PMID 18006322
- ^ Hiroshi Ohta; Tomoko Ishizaka; Makoto Tatsuzuki; Mitsukane Yoshinaga; Izumi Iida; Yasumitsu Tomishima; Yoshihisa Toda; Shuji Saito (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB2 cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6299–6304. doi:10.1016/j.bmcl.2007.09.004. PMID 17884496.
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |